December 17, 2009
CLEVELANDThe probiotic strain, Bacillus coagulans GBI-30, PTA-6086, trademarked by Ganeden Biotech as GanedenBC30, was significantly more effective than placebo in providing relief to subjects suffering from intestinal gas in a clinical study published in BMC Gastroenterology (2009 Nov 18;9:85).
The randomized, double blind, placebo-controlled study found subjects taking Digestive Advantage Gas Defense Formula, an over-the-counter (OTC) product marketed by Ganeden Biotech that contains the Bacillus coagulans probiotic strain, experienced statistically significant improvement versus placebo in the Gastrointestinal Symptom Rating Scale (GSRS) total score during the four weeks of product use. The authors of the study concluded Digestive Advantage Gas Defense Formula was effective in improving the quality of life and reducing gastrointestinal (GI) symptoms in adults with intestinal gas symptoms and no GI diagnoses.
We were impressed by the results given the strong placebo effect present in this study, a phenomenon quite common in studies involving subjective measures, said Douglas Kalman, Ph.D., R.D., author of the 61-subject study and fellow of the American College of Nutrition. Although Bacillus coagulans has previously been shown to be effective for serious GI disorders, such as IBS and antibiotic associated diarrhea, this study suggests that the general population can also benefit and address a common GI complaint.
Ganeden Biotech provided a research grant to help fund the study.
You May Also Like